These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26364274)

  • 1. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.
    Schade S; Paulus W
    Int J Neuropsychopharmacol; 2016 Apr; 19(4):. PubMed ID: 26364274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
    Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
    Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
    Goff DC; Tsai G; Manoach DS; Coyle JT
    Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
    Cascella NG; Macciardi F; Cavallini C; Smeraldi E
    J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preliminary study of D-cycloserine treatment in Alzheimer's disease.
    Tsai GE; Falk WE; Gunther J
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):224-6. PubMed ID: 9608414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury.
    Yaka R; Biegon A; Grigoriadis N; Simeonidou C; Grigoriadis S; Alexandrovich AG; Matzner H; Schumann J; Trembovler V; Tsenter J; Shohami E
    FASEB J; 2007 Jul; 21(9):2033-41. PubMed ID: 17351125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
    Kushner MG; Kim SW; Donahue C; Thuras P; Adson D; Kotlyar M; McCabe J; Peterson J; Foa EB
    Biol Psychiatry; 2007 Oct; 62(8):835-8. PubMed ID: 17588545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
    Goff DC
    Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
    van Berckel BN; Lipsch C; Gispen-de Wied C; Wynne HJ; Blankenstein MA; van Ree JM; Kahn RS
    Psychopharmacology (Berl); 1998 Jul; 138(2):190-7. PubMed ID: 9718289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators.
    Yao L; Zhou Q
    Neural Plast; 2017; 2017():2875904. PubMed ID: 28163934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NMDA modulation in scopolamine dementia.
    Jones RW; Wesnes KA; Kirby J
    Ann N Y Acad Sci; 1991; 640():241-4. PubMed ID: 1837979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-Cycloserine enhances conditioned taste aversion learning in rats.
    Nunnink M; Davenport RA; Ortega B; Houpt TA
    Pharmacol Biochem Behav; 2007; 87(3):321-30. PubMed ID: 17561237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions.
    Langton JM; Richardson R
    Neuropsychopharmacology; 2008 Dec; 33(13):3096-102. PubMed ID: 18354389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.
    Tang W; Liu D; Traynelis SF; Yuan H
    Neuropharmacology; 2020 Oct; 177():108247. PubMed ID: 32712275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of AICP as a GluN2C-Selective
    Jessen M; Frederiksen K; Yi F; Clausen RP; Hansen KB; Bräuner-Osborne H; Kilburn P; Damholt A
    Mol Pharmacol; 2017 Aug; 92(2):151-161. PubMed ID: 28588066
    [No Abstract]   [Full Text] [Related]  

  • 16. The Therapeutic Role of d-Cycloserine in Schizophrenia.
    Goff D
    Adv Pharmacol; 2016; 76():39-66. PubMed ID: 27288073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
    Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
    Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of D-cycloserine on the behavior and ERK activity in the amygdala: role of individual anxiety levels.
    Wu SL; Hsu LS; Tu WT; Wang WF; Huang YT; Pawlak CR; Ho YJ
    Behav Brain Res; 2008 Mar; 187(2):246-53. PubMed ID: 17959260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-Cycloserine lowers kynurenic acid formation--new mechanism of action.
    Baran H; Kepplinger B
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):639-44. PubMed ID: 24189377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.
    Krystal JH; D'Souza DC; Petrakis IL; Belger A; Berman RM; Charney DS; Abi-Saab W; Madonick S
    Harv Rev Psychiatry; 1999; 7(3):125-43. PubMed ID: 10483932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.